NYSE$IBIO
iBio Inc · Q4 2022 earnings
Q4 2022 earnings · · Investor relations
Briefing
iBio reported preliminary unaudited financial results for fiscal year 2022 and provided a corporate update.
iBio reported FY 2022 revenues of $2.4 million, a 1% increase over fiscal 2021. The company's net loss for the year was $50.3 million. iBio held $39.5 million in cash, cash equivalents, and investments as of June 30, 2022.
- iBio acquired RubrYc Therapeutics' assets, including an AI-powered drug discovery platform and four new immunotherapy candidates.
- The company now wholly-owns its lead immune-oncology asset, IBIO-101, with no further financial commitments and expects to file an IND application in the first half of calendar 2024.
- iBio decided not to proceed with an IND submission for IBIO-202, its multi-variant COVID-19 vaccine candidate, due to challenge study data.
- iBio's stockholders approved a proposal giving the Board the option to effect a one for twenty-five (1-for-25) reverse stock split.
Headline financials
Revenue & EPS history
iBio · Revenue · Quarterly
$61K
Forward guidance
iBio is evaluating options to expand its cash runway, including lowering expenses, focusing product development, selling or out-licensing assets, raising capital, and seeking grant revenue or collaborations.
Tailwinds
- Lowering expenses through decreasing spending
- Focusing product development on a select number of product candidates
- Sale or out-licensing of certain product candidates or parts of the business
- Raising money from capital markets
- Grant revenue or collaborations, or a combination thereof
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2022
-1.4%
Avg return
Earnings day
-2.9%
Avg return
5 days after
+14.3%
Avg return
30 days after
43%
17 / 40 earnings
Positive
+24.4%
Q3 2020
Best reaction
-34.4%
Q4 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2026 | +12.9% | +9.9% | +22.8% | |
| Q1 2026 | -8.0% | -3.2% | +55.2% | |
| Q4 2025 | +3.7% | +8.6% | +6.2% | |
| Q3 2025 | +1.3% | +1.3% | +30.4% | |
| Q2 2025 | -14.8% | -7.8% | +49.2% | |
| Q1 2025 | -9.4% | -10.9% | -2.0% | |
| Q4 2024 | -2.6% | -4.2% | +51.1% | |
| Q3 2026 | -3.7% | +23.9% | +36.2% | |
| Q3 2024 | +1.6% | +7.0% | +37.8% | |
| Q2 2024 | +5.2% | +5.2% | +2.6% | |
| Q1 2024 | -3.4% | -10.3% | -78.1% | |
| Q4 2023 | -3.3% | -9.1% | -6.1% | |
| Q3 2023 | -7.9% | -5.9% | -31.7% | |
| Q2 2023 | -10.5% | +55.8% | +113.7% | |
| Q1 2023 | +0.0% | -8.6% | -68.6% | |
| Q4 2022 | -34.4% | -46.9% | -74.6% | |
| Q3 2022 | +0.0% | +0.0% | +12.0% | |
| Q2 2022 | +2.7% | -8.1% | -5.4% | |
| Q1 2022 | -9.2% | -11.8% | -17.1% | |
| Q4 2021 | -4.3% | -11.1% | -35.0% | |
| Q3 2021 | -6.8% | -0.7% | +5.4% | |
| Q2 2021 | -15.3% | -17.8% | -29.8% | |
| Q1 2021 | +15.2% | -9.6% | -38.2% | |
| Q3 2020 | +24.4% | +16.0% | +31.9% | |
| Q2 2020 | -10.5% | -21.1% | +321.1% | |
| Q1 2020 | +13.3% | -26.7% | +46.7% | |
| Q3 2019 | +7.3% | -2.4% | -4.9% | |
| Q2 2019 | -2.2% | -4.4% | -6.7% | |
| Q1 2019 | +4.0% | +9.3% | -10.7% | |
| Q1 2015 | +3.4% | — | — | |
| Q1 2014 | +0.0% | — | — | |
| Q1 2013 | -1.9% | — | — | |
| Q3 2012 | -9.8% | — | — | |
| Q1 2010 | +1.8% | — | — | |
| Q1 2012 | +1.8% | — | — | |
| Q4 2011 | -3.0% | — | — | |
| Q3 2011 | +4.8% | — | — | |
| Q2 2010 | +3.4% | — | — | |
| Q4 2010 | +1.4% | — | — | |
| Q3 2010 | -1.0% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro